Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor

Growth Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Extracellular Domain ◽

Vascular Endothelial ◽

First Line ◽

Predictive Values ◽

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3529 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3529-3529 ◽

Cited By ~ 1

Author(s):

W. F. Novotny ◽

E. Holmgren ◽

B. Nelson ◽

R. Mass ◽

F. Kabbinavar ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Venous Thromboembolism ◽

Growth Factor ◽

Metastatic Colorectal Cancer ◽

Vascular Endothelial ◽

First Line ◽

Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

BMC Cancer ◽

10.1186/1471-2407-9-421 ◽

2009 ◽

Vol 9 (1) ◽

Cited By ~ 5

Author(s):

Sachin Kumar ◽

Randeep Guleria ◽

Vikas Singh ◽

Alok C Bharti ◽

Anant Mohan ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Vascular Endothelial ◽

Small Cell Lung ◽

First Line ◽

A Phase II Trial of Humanized Anti-Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen-Independent Prostate Cancer

The Prostate Journal ◽

10.1046/j.1525-1411.2001.32007.x ◽

2001 ◽

Vol 3 (2) ◽

pp. 65-70 ◽

Cited By ~ 55

Author(s):

David M. Reese ◽

Paige Fratesi ◽

Michelle Corry ◽

William Novotny ◽

Eric Holmgren ◽

...

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Vascular Endothelial ◽

Androgen Independent

Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO)

Annals of Oncology ◽

10.1093/annonc/mdw388.11 ◽

2016 ◽

Vol 27 ◽

pp. vi486

Author(s):

L. Lebellec ◽

F. Bertucci ◽

E. Tresch-Bruneel ◽

E. Bompas ◽

Y. Toiron ◽

...

Keyword(s):

Growth Factor ◽

Prognostic Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Progression Free Survival ◽

Vascular Endothelial ◽

Free Survival ◽

Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-10-0974 ◽

2010 ◽

Vol 16 (21) ◽

pp. 5320-5328 ◽

Cited By ~ 37

Author(s):

Setsuko K. Chambers ◽

Mary C. Clouser ◽

Amanda F. Baker ◽

Denise J. Roe ◽

Haiyan Cui ◽

...

Keyword(s):

Ovarian Cancer ◽

Growth Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Vascular Endothelial ◽

Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials

Tumor Biology ◽

10.1007/s13277-015-4493-9 ◽

2015 ◽

Vol 37 (5) ◽

pp. 6297-6306

Author(s):

Yan Li ◽

Xin-Yue Liang ◽

Yi-Qi Yue ◽

Lei Sheng ◽

Ji-Kai Liu ◽

...

Keyword(s):

Clinical Trials ◽

Growth Factor ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Complete Response ◽

Vascular Endothelial ◽

First Line ◽

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3529 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3529-3529 ◽

Cited By ~ 4

Author(s):

W. F. Novotny ◽

E. Holmgren ◽

B. Nelson ◽

R. Mass ◽

F. Kabbinavar ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Venous Thromboembolism ◽

Growth Factor ◽

Metastatic Colorectal Cancer ◽

Vascular Endothelial ◽

First Line ◽

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)

Oncotarget ◽

10.18632/oncotarget.12172 ◽

2016 ◽

Vol 7 (45) ◽

pp. 73984-73994 ◽

Cited By ~ 12

Author(s):

Loic Lebellec ◽

François Bertucci ◽

Emmanuelle Tresch-Bruneel ◽

Emmanuelle Bompas ◽

Yves Toiron ◽

...

Keyword(s):

Growth Factor ◽

Phase Ii ◽

Predictive Factor ◽

Phase Ii Trial ◽

Progression Free Survival ◽

Vascular Endothelial ◽

Free Survival ◽

A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti-Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema

Yearbook of Ophthalmology ◽

10.1016/s0084-392x(08)70316-2 ◽

2006 ◽

Vol 2006 ◽

pp. 134-135

Author(s):

J.F. Vander

Keyword(s):

Growth Factor ◽

Macular Edema ◽

Diabetic Macular Edema ◽

Phase Ii ◽

Vascular Endothelial ◽

A PHASE II RANDOMIZED DOUBLE-MASKED TRIAL OF PEGAPTANIB, AN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR APTAMER, FOR DIABETIC MACULAR EDEMA

Evidence-Based Ophthalmology ◽

10.1097/01.ieb.0000209784.62228.22 ◽

2006 ◽

Vol 7 (2) ◽

pp. 69-70

Author(s):

Caroline Baumal

Keyword(s):

Growth Factor ◽

Macular Edema ◽

Diabetic Macular Edema ◽

Phase Ii ◽

Vascular Endothelial ◽